Celator Pharmaceuticals Inc.'s CEO Scott Jackson and President Lawrence Mayer Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - Apr 22, 2015) - Celator Pharmaceuticals Inc.'s (NASDAQ: CPXX) remarkable drug combination strategy has produced a cancer-fighting duo endowed with a coveted fast-track designation. Scott Jackson, the company's CEO, and Lawrence Mayer, president, chief scientific officer and founder, tell The Life Sciences Report about what sets Celator apart, and reveal profit-generating milestones that investors should keep on their scopes.

The Life Sciences Report: Please give us an overview of your company, Celator Pharmaceuticals Inc.

Scott Jackson: Celator Pharmaceuticals is an oncology-focused biopharmaceutical company. Our mission is to improve and extend the lives of patients with cancer by transforming the science of combination therapy.

Most cancer patients are treated with combinations of drugs. Our proprietary technology platform, which we call CombiPlex, has resulted in our most advanced product candidate, CPX-351, a combination of two drugs, cytarabine and daunorubicin. We have recently completed a Phase 3 study of CPX-351 for patients with a form of acute myeloid leukemia, commonly referred to as secondary AML. To be clear, this is first-line therapy. We will have initial data from the Phase 3 study in Q2/15 for what's called induction response rate, which is a secondary endpoint. The primary endpoint is overall survival, and we expect that to be available in...

Continue reading this interview with Scott Jackson and Lawrence Mayer: Celator's New Drug Combo Will Revolutionize AML Standard of Care

About Streetwise Reports - The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends.

DISCLOSURE:
Celator Pharmaceuticals Inc. paid The Life Sciences Report to conduct, produce and distribute the interview. Scott Jackson and Lawrence Mayer had final approval of the content and are wholly responsible for the validity of the statements. Opinions expressed are the opinions of Scott Jackson and Lawrence Mayer, and not of The Life Sciences Report or its officers.